Antifibrotic therapy and its indications for interstitial pulmonary fibrosis
Authors:
Martina Doubková
Authors‘ workplace:
Klinika nemocí plicních a TBC Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity Brno
Published in:
Vnitř Lék 2022; 68(4): 212-215
Category:
Main Topic
Overview
Idiopathic pulmonary fibrosis and chronic fibrotic interstitial lung disease with progressive phenotype are characterized by fibrotic lung parenchyma. Current antifibrotic treatment does not affect pre-existing lung parenchyma fibrosis, but prevents fibrosis progression and reduces mortality by reducing fibrotization. This work summarizes fibrotic lung processes and their treatment options.
Keywords:
idiopathic pulmonary fibrosis – nintedanib – progressive fibrosing interstitial lung diseases – pirfenidon
Sources
1. Travis WD, Costabel U, Hansell DM et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48.
2. Vašáková M, Šterclová M. Idiopatická plicní fibróza (Doporučený postup pro diagnózu, léčbu a sledování – 2. aktualizace). http://www.pneumologie.cz. Cited dne 11. 3. 2022.
3. Raghu G, Rochwerg B, Zhang Y et al.; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/ JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm. 201506-1063ST.
4. Raghu G, Remy‑Jardin M, Myers JL et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
5. Cottin V, Wollin L, Fischer A et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100. doi: 10.1183/16000617.0100-2018.
6. Šterclová M. Definice progredujících fibrotizujících intersticiálních plicních procesů a přístup k nemocnému (Doporučený postup). https://www.pneumologie.cz. Navštíveno dne 11. 3. 2022.
7. Žurková M, Lošťáková V, Vašáková M et al. Sarkoidóza (Doporučený postup). https://www. pneumologie.cz. Cited dne 11. 3. 2022.
8. Takeda Y, Tsujino K, Kijima T et al. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence. 2014;8:361-70. doi: 10.2147/PPA.S37233.
9. Kurita Y, Araya J, Minagawa S et al. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respir Res. 2017;18(1):114. doi: 10.1186/s12931-017-0600-3.
10. Noble PW, Albera C, Bradford WZ et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4.
11. King TE Jr, Bradford WZ, Castro‑Bernardini S et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92. doi: 10.1056/NEJMoa1402582.
12. Nathan SD, Albera C, Bradford WZ et al. Effect of pirfenidone on mortality: pooled analyses and meta‑analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5.
13. Wollin L, Wex E, Pautsch A et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434-45. doi: 10.1183/09031936.00174914.
14. Richeldi L, Costabel U, Selman M et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-87. doi: 10.1056/ NEJMoa1103690.
15. Richeldi L, du Bois RM, Raghu G et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82. doi: 10.1056/NEJMoa1402584.
16. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710.
17. Flaherty KR, Wells AU, Cottin V et al. INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727. doi: 10.1056/NEJMoa1908681.
18. Distler O, Highland KB, Gahlemann M et al. SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis‑Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 4
Most read in this issue
- Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease – where they are effective and where they are not
- Acetylsalicylic acid in primary prevention of cardiovascular disease
- COVID-19 and post-COVID – Jekyll and Hyde of modern medicine
- Acute kidney injury due to antimicrobial therapy